Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:LENS

Presbia (LENS) Stock Price, News & Analysis

Presbia logo

About Presbia Stock (NASDAQ:LENS)

Advanced Chart

Key Stats

Today's Range
$32.18
$32.21
50-Day Range
$0.07
$0.32
52-Week Range
$0.23
$5.50
Volume
822 shs
Average Volume
122,366 shs
Market Capitalization
$554.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive LENS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Presbia and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LENS Stock News Headlines

Contact Lens King Coupons
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.tc pixel
Real and virtual images
Types of lens
Convex and concave lenses
See More Headlines

LENS Stock Analysis - Frequently Asked Questions

Presbia PLC (NASDAQ:LENS) issued its quarterly earnings results on Friday, August, 12th. The medical instruments supplier reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.07. The medical instruments supplier had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.04 million. Presbia had a negative net margin of 36,604.35% and a negative trailing twelve-month return on equity of 414.02%.

Presbia (LENS) raised $50 million in an initial public offering on Thursday, January 29th 2015. The company issued 4,200,000 shares at $11.00-$13.00 per share. Jefferies acted as the underwriter for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Presbia investors own include Ritter Pharmaceuticals (RTTR), AcelRx Pharmaceuticals (ACRX), Allena Pharmaceuticals (ALNA), Bellatrix Exploration (BXE), Second Sight Medical Products (EYES), Lilis Energy (LLEX) and Marinus Pharmaceuticals (MRNS).

Company Calendar

Last Earnings
8/12/2016
Today
9/16/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:LENS
CIK
1591096
Fax
N/A
Employees
24
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.41 million
Net Margins
-36,604.35%
Pretax Margin
N/A
Return on Equity
-414.02%
Return on Assets
-195.56%

Debt

Debt-to-Equity Ratio
1.24
Current Ratio
2.88
Quick Ratio
2.82

Sales & Book Value

Annual Sales
$20 thousand
Price / Sales
27,735.22
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.09 per share
Price / Book
357.71

Miscellaneous

Outstanding Shares
17,230,000
Free Float
N/A
Market Cap
$554.70 million
Optionable
Not Optionable
Beta
2.57
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:LENS) was last updated on 9/16/2025 by MarketBeat.com Staff
From Our Partners